Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations

Colorectal cancer (CRC) is the third most prevalent cancer in the world. The PD-1/PD-L1 pathway plays a crucial role in modulating immune response to cancer, and PD-L1 expression has been observed in tumor and immune cells within the tumor microenvironment of CRC. Thus, immunotherapy drugs, specific...

Full description

Bibliographic Details
Main Authors: Xiang Chen, Ling-Juan Chen, Xiao-Fei Peng, Ling Deng, Yan Wang, Jiu-Jiang Li, Dong-Li Guo, Xiao-Hua Niu
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Translational Oncology
Subjects:
Colorectal cancer
Immune checkpoint receptors
Monoclonal antibodies
Programmed cell death‐1
Programmed cell death‐ligand 1
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523323002371

Internet

http://www.sciencedirect.com/science/article/pii/S1936523323002371

Similar Items